HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As US Hemp Product Industry Grows Without Regulatory Clearance, It Has Grown In Compliance

Executive Summary

“For companies like Joy Organics, we view it as an advantage that CBD is not currently regulated as a dietary supplement,” says COO Todd Smith. Advantage is borne from hemp ingredient supplements not becoming commoditized, keeping prices from falling. Meanwhile, industry’s maturity can be seen in compliance with FDA rules.

You may also be interested in...



Making Hemp Lawful As Dietary Ingredient In US Could Be More Than Marketers Bargain For

Marketers of supplements containing hemp-derived cannabinoids aren’t particularly proficient at meeting FDA's regulatory requirements, says Rodney Butt of consultancy Nutrasource Pharmaceutical and Nutraceutical Services.

US Cannabis Legalization Cultivated By House Has Thorny Forecast For Harvest In Senate

Absence of hemp provisions in House bill could be a problem with Senate Democrats, who have drafted legislation not only on producing, marketing and possessing marijuana but also using in supplements ingredients classified as hemp. Still, Senate passage of cannabis legalization is unlikely.

Emerging US Cannabinoid Market Sales Driver Could Drive Lawful Use Legislation Off The Rails

Delta-8 THC is a close chemical cousin to the substance recognized for intoxicating effects. Its effects aren't a settled question, along with whether it meets definition of hemp stated in 2018 farm bill.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel